Cargando…

Nephrotic syndrome associated with gemcitabine use in a patient with ovarian cancer

BACKGROUND: Here we present a patient who developed nephrotic syndrome associated with gemcitabine use. CASE REPORT: Gemcitabine therapy was initiated following tumor recurrence in a patient with ovarian cancer, who was previously treated twice with carboplatin and paclitaxel. Radiological findings...

Descripción completa

Detalles Bibliográficos
Autores principales: Ata, Alper, Gürses, İclal, Kıykım, Ahmet, Arıcan, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3614261/
https://www.ncbi.nlm.nih.gov/pubmed/23569546
http://dx.doi.org/10.12659/AJCR.883583
Descripción
Sumario:BACKGROUND: Here we present a patient who developed nephrotic syndrome associated with gemcitabine use. CASE REPORT: Gemcitabine therapy was initiated following tumor recurrence in a patient with ovarian cancer, who was previously treated twice with carboplatin and paclitaxel. Radiological findings waned and tumor marker concentrations decreased after gemcitabine treatment. However, edema and ascites development was observed on the fifth treatment cycle. Laboratory results revealed increased blood urea nitrogen and creatinine levels, decreased serum albumin concentrations, and increased 24-hour urinary protein excretion. Renal biopsy findings were compatible with membranous glomerulonephritis. Gemcitabine administration was stopped and the cyclophosphamide and steroid therapy were initiated. The symptoms and findings disappeared after the cessation of gemcitabine and immunosuppressive treatment. CONCLUSIONS: Gemcitabine treatment may be associated with proteinuria to the extent of nephrotic syndrome.